首页> Cancers> Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence.

Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence.

导出 OA

翻译打印收藏纠错

第一作者： Aswathy R,Devan

第一单位： Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India.

作者： Aswathy R,Devan ^[1] ; Bhagyalakshmi,Nair ^[1] ; Manu Kanjoormana,Aryan ^[2] ; Vijayastelar B,Liju ^[3] ; Joel Joy,Koshy ^[1] ; Bijo,Mathew ^[4] ; Arun,Valsan ^[5] ; Hoon,Kim ^[6] ; Lekshmi R,Nath ^[1]

作者单位： Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India. ^[1] Department of Immunology, Amala Cancer Research Centre, Thrissur 680555, Kerala, India. ^[2] The Shraga Segal Department of Microbiology-Immunology and Genetics, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel. ^[3] Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India. ^[4] Department of Gastroenterology and Epatology, Amrita Institute of Medical Science, Kochi 682041, Kerala, India. ^[5] Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea. ^[6]

关键词 HCC adjunct immunotherapy curative treatment immune checkpoint inhibitors immunosuppression recurrence

DOI 10.3390/cancers15102729

PMID 37345066

发布时间 2023-07-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交